Parving H-H .Renoprotection in diabetes: genetic and non-genetic risk factors and treatment.Diabeticoligia1998;41:745-59.
2.
Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M.Long term stabilising effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetics . Ann Int Med1993;118:577-81.
3.
Dinneen SF, Gerstein HCThe association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic review of the literature. Arch Int Med1997; 157(13):1413-8.
4.
Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation1999;100:1134-46.
5.
Haffner SM, Lehto S., Ronnemaa T., Pyorala K., Laakso M.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med1998;339:229-34.
6.
The Hypertension in Diabetes Study Group.Hypertension in diabetes study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens1993;11:319-25.
7.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RDThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy .NEnglJMed1993;329:1456-62.
8.
Viberti G., Mongensen CE, Groop LC, Pauls JFfor the European MicroalbuminuriaCaptopril Study Group.Effect of captopril on progression to clinical proteinuria in patients with insulin dependent diabetes and microalbuminuria . J Am Med Assoc1994;271:275-9.
9.
Björck S., Mulek H., Johnsen SA, Nordén G.,Aurell M.Renal protective effect of enalapril in diabetic nephropathy. BMJ1992;304:330-43.
10.
Heart Out comes Prevention Evaluation (HOPE) Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet2000;355:253-9.
11.
Tatti P., Pahor M., Byington RP et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomised trial (FACET) in patients with hypertension and NIDMM. Diabetes Care1998;21:597-603.
12.
Estacio RO, Jeffers BW, Hiatt RA, Biggerstaff SL, Gifford N., Schrier RWThe effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension . N Engl J Med1998;338:645-52.
13.
Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet1998 ;351:1755-62.
14.
Tuomillehto J., Rastenyte D.,Thisj L., Staessen J.Reduction of mortality and cardiovascular events in older diabetic patients with isolated systolic hypertensionin Europe treated with nitrendipine-based antihypertensive therapy (Syst-Eur Trial) (Abstract)Diabetes Care1998;47:A57.
15.
UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998;317:703-13.
16.
UK Prospective Diabetes Study Group.Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ1998; 317:713-20.
17.
Parving H-H. , Lehnert, H., Bröchner-Mortensen J., Gomis R., Andersen S., Arner P. for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.NEnglJMed2001;345:870-8.
18.
Lewis EJ, Hunsicker LG, Clarke WR et al. for the Collaborative Study Group.Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001;345:851-60.
19.
Brenner BM, Cooper ME, de Zeeuw D. et al. for the RENAAL Study Investigators.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.NEnglJMed2001;345:861-9.
20.
Rodby RA, Rohde RD, Clarke WR et al. for the Collaborative Study Group.The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrol Dial Transplant2000;15:487-97.
21.
Brenner BM, Cooper ME, de Zeeuw D. et al. for the RENAAL Study Investigators.The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). JRAAS2000;1(4):328-35.
22.
Amos AF, McCarthy DJ, Zimmet P.The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med1997;14:S7-S85.
23.
USRDS: Annual Data Report.Chapter 5. Patient mortality and survival. 1995;91-108, www.usrds.org
24.
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet1997;349:1857-63.
25.
Ruggeneti P. , Perna A., Gherardi G., Garini G., Zoccali C., Salvadori M., Scolari F., Schena FP, Remuzzi G.Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet1999;354:359-64.
26.
Aggodoa YA, Appel L., Bakris GL et al. for the African American Study of Kidney Disease and Hypertension (AASK) Study Group.Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis. A Randomised Controlled Trial. JAMA2001;285:2719-28.
27.
Anderson S. ,Tarnow L., Rossing P., Hansen BV, Parving HHRenoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int2000;57:601-6.
